Accounts Receivable, after Allowance for Credit Loss, Current of EVmo, Inc. from 30 Sep 2019 to 31 Mar 2023

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
EVmo, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 30 Sep 2019 to 31 Mar 2023.
  • EVmo, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 31 Mar 2023 was $844,604, a 10% increase year-over-year.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

EVmo, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2023 $844,604 +$80,126 +10% 31 Mar 2023 10-Q 22 May 2023 2023 Q1
Q4 2022 $919,245 +$167,795 +22% 31 Dec 2022 10-Q 22 May 2023 2023 Q1
Q3 2022 $785,487 +$149,751 +24% 30 Sep 2022 10-Q 18 Nov 2022 2022 Q3
Q2 2022 $795,037 +$366,414 +85% 30 Jun 2022 10-Q 15 Aug 2022 2022 Q2
Q1 2022 $764,478 +$722,843 +1736% 31 Mar 2022 10-Q 16 May 2022 2022 Q1
Q4 2021 $751,450 +$632,211 +530% 31 Dec 2021 10-K 21 Apr 2023 2022 FY
Q3 2021 $635,736 +$582,398 +1092% 30 Sep 2021 10-Q 15 Nov 2021 2021 Q3
Q2 2021 $428,623 +$385,061 +884% 30 Jun 2021 10-Q 16 Aug 2021 2021 Q2
Q1 2021 $41,635 +$3,796 +10% 31 Mar 2021 10-Q 17 May 2021 2021 Q1
Q4 2020 $119,239 +$59,908 +101% 31 Dec 2020 10-K 31 Mar 2022 2021 FY
Q3 2020 $53,338 -$25,305 -32% 30 Sep 2020 10-Q 12 Nov 2020 2020 Q3
Q2 2020 $43,562 30 Jun 2020 10-Q 06 Aug 2020 2020 Q2
Q1 2020 $37,839 31 Mar 2020 10-Q 18 May 2020 2020 Q1
Q4 2019 $59,331 31 Dec 2019 10-K 31 Mar 2021 2020 FY
Q3 2019 $78,643 30 Sep 2019 10-Q 23 Dec 2019 2019 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.